Published in Med Oncol Tumor Pharmacother on January 01, 1991
Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology (1992) 2.78
No safe haven: a study of violence exposure in an urban community. J Am Acad Child Adolesc Psychiatry (1995) 2.28
Insulin adsorption to three-liter ethylen vinyl acetate bags during 24-hour infusion. JPEN J Parenter Enteral Nutr (1990) 2.05
Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum (1999) 2.03
Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol (2006) 1.90
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem (2009) 1.60
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol (2004) 1.56
Cauda equina syndrome: evaluation of the clinical outcome. Eur Rev Med Pharmacol Sci (2014) 1.53
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
Soft tissue metastases in lung cancer: a review of the literature. Eur Rev Med Pharmacol Sci (2012) 1.45
Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer (1998) 1.40
Antithrombin III in patients with hepatocellular carcinoma. Thromb Haemost (1987) 1.39
Structured versus long-chain triglycerides: a safety, tolerance, and efficacy randomized study in colorectal surgical patients. JPEN J Parenter Enteral Nutr (1999) 1.39
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet (2004) 1.33
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol (2009) 1.30
Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum (1998) 1.28
Rotavirus vaccine administered parenterally induces protective immunity. J Virol (1993) 1.27
Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol (1998) 1.23
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol (2006) 1.18
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology (2006) 1.16
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys (2001) 1.12
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer (2007) 1.12
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif (2011) 1.11
Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys (1998) 1.09
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother (2000) 1.07
Thymoma in patients with MG: characteristics and long-term outcome. Neurology (2002) 1.06
Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog (1999) 1.05
Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine (1999) 1.03
Isolated splenic metastasis from colon cancer. J Exp Clin Cancer Res (2004) 1.03
How can the assessment of fistula-inano be improved? Dis Colon Rectum (2000) 1.02
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Hum Mutat (2001) 1.01
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. Br J Cancer (2012) 1.01
Analysis of host range restriction determinants in the rabbit model: comparison of homologous and heterologous rotavirus infections. J Virol (1998) 1.01
Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology (Oxford) (2000) 1.00
Short-term sacral nerve stimulation for functional anorectal and urinary disturbances: results in 40 patients: evaluation of a new option for anorectal functional disorders. Dis Colon Rectum (2001) 0.99
Peritoneal mesothelioma in recurrent familial peritonitis. J Clin Gastroenterol (1997) 0.99
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer (2009) 0.98
Circadian variations of epithelial cell proliferation in human rectal crypts. Gastroenterology (1994) 0.98
Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol (1999) 0.98
Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer. Curr Med Res Opin (2010) 0.96
Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer (2011) 0.96
MLH1 and MSH2 constitutional mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer. Int J Cancer (1998) 0.95
Preoperative parenteral nutrition in the high risk surgical patient. JPEN J Parenter Enteral Nutr (1988) 0.94
Somatostatin in paroxysmal supraventricular and junctional tachycardia. Br Med J (Clin Res Ed) (1984) 0.94
Megaloblastic anemia due to folic acid deficiency after oral contraceptives. Haematologica (1979) 0.94
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer (2003) 0.94
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer (2007) 0.94
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol (2009) 0.93
Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum (1996) 0.93
Rotavirus disease, but not infection and development of intestinal histopathological lesions, is age restricted in rabbits. Virology (1998) 0.93
Neuromodulation for fecal incontinence: outcome in 16 patients with definitive implant. The initial Italian Sacral Neurostimulation Group (GINS) experience. Dis Colon Rectum (2001) 0.93
Familial 1.1 Mb deletion in chromosome Xq22.1 associated with mental retardation and behavioural disorders in female patients. Eur J Med Genet (2010) 0.92
Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer (1997) 0.92
Selection of locally advanced gastric carcinoma by preoperative staging laparoscopy. Surg Endosc (1997) 0.92
The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol (2011) 0.91
Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer (2002) 0.90
Ketoalkalosis as a result of triple derangement of acid-base equilibrium in a diabetic patient. Acta Diabetol Lat (1985) 0.90
Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome. Cancer (1999) 0.90
Local excision and external beam radiotherapy in early rectal cancer. Int J Radiat Oncol Biol Phys (1996) 0.90
A prevalence study of celiac disease in persons with Down syndrome residing in the United States of America. Acta Paediatr (1999) 0.89
The Pediatric Risk of Mortality (PRISM) Score and Injury Severity Score (ISS) for predicting resource utilization and outcome of intensive care in pediatric trauma. Crit Care Med (1999) 0.89
Gastro-intestinal symptoms as clinical manifestation of peritoneal and retroperitoneal spread of an invasive lobular breast cancer: report of a case and review of the literature. BMC Cancer (2006) 0.89
S100A13, a new marker of angiogenesis in human astrocytic gliomas. J Neurooncol (2006) 0.89
Prognostic factors in colorectal cancer: current status and new trends. J Surg Oncol Suppl (1991) 0.89
Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group. Tech Coloproctol (2013) 0.88
The persistence of electrostatically seeded endothelial cells lining a small diameter expanded polytetrafluoroethylene vascular graft. J Biomater Appl (2001) 0.88
Homocysteine and related genetic polymorphisms in Down's syndrome IQ. J Neurol Neurosurg Psychiatry (2005) 0.88
LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci (2013) 0.88
The role of surgical treatment in colon diverticulitis: indications and results. Ann Ital Chir (2000) 0.87
Duplex scanning of neck vessels: need for extending the consensus on indications. Neurol Sci (2002) 0.87
[Late complication after colon self-expandable metal stent placement: a case report]. Minerva Chir (2007) 0.87
Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis (1996) 0.86
Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECA-CC2). Acta Chir Iugosl (2010) 0.86
Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol (R Coll Radiol) (2010) 0.85
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. Oncol Rep (2006) 0.85
Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. J Cell Physiol (2010) 0.85
Three new patients with dup(17)(p11.2p11.2) without autism. Clin Genet (2008) 0.85
Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer (1996) 0.85
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep (2010) 0.85